Loading the player...

3:18 MD /Alert Exclusive

NEXT UP
Time to Treatment Completion Associated with Poor Breast Cancer Survival

Breaking Study Finds Optimal Screening Interval for Breast Cancer

Despite breast cancer being one of the most common cancers among women in the United States, there are still questions about when and how often women should be screened. A recent study showed that annual mammograms have more benefits than a longer duration between screenings.

Next Up In Breast Cancer

Adding Tucatinib to Trastuzumab and Capecitabine Improves HER2-positive Breast Cancer Survival

Adding Tucatinib to Trastuzumab and Capecitabine Improves HER2-positive Breast Cancer Survival

Breast Cancer Survivors Report Cognitive Impairment After PPI Use

Breast Cancer Survivors Report Cognitive Impairment After PPI Use

New Breast Cancer Therapy Shows Significant Response

New Breast Cancer Therapy Shows Significant Response

Early Study Results show Abemaciclib Reduces Risk of Recurrence in HR+ HER2- Breast Cancer

Early Study Results show Abemaciclib Reduces Risk of Recurrence in HR+ HER2- Breast Cancer

FDA Issues Warning Alert for Atezolizumab/Paclitaxel Combo in TNBC

FDA Issues Warning Alert for Atezolizumab/Paclitaxel Combo in TNBC

Celecoxib Shows No Benefit for Patients with Early Breast Cancer

Celecoxib Shows No Benefit for Patients with Early Breast Cancer

Adding Capecitabine to TDM-1 Demonstrates No Benefit in Breast Cancer Patients

Adding Capecitabine to TDM-1 Demonstrates No Benefit in Breast Cancer Patients

RNA TROJAN Promotes Triple-Negative Breast Cancer Progression

RNA TROJAN Promotes Triple-Negative Breast Cancer Progression

Study Shows Breastfeeding Can be Safe for Breast Cancer Survivors

Study Shows Breastfeeding Can be Safe for Breast Cancer Survivors

Mindfulness Shows Benefits for Young Breast Cancer

Mindfulness Shows Benefits for Young Breast Cancer

New ASCO, ASTRO, SSO Joint Clinical Guidelines for Hereditary Breast Cancer

New ASCO, ASTRO, SSO Joint Clinical Guidelines for Hereditary Breast Cancer

1:52 MD /Alert Exclusive

FDA Approves Mammography Screening Artificial Intelligence Tool

Advanced ER+ HER2+ Breast Cancer Combo Therapy Fails to Improve Outcomes

Advanced ER+ HER2+ Breast Cancer Combo Therapy Fails to Improve Outcomes

Various Breast Cancer Research Challenges in Recurrence, Triple Negative BC

Various Breast Cancer Research Challenges in Recurrence, Triple Negative BC

FDA Committee Delays Approval of Pembrolizumab for Early TNBC

FDA Committee Delays Approval of Pembrolizumab for Early TNBC

EU approves HER2+ Metastatic Breast Cancer Treatment

EU approves HER2+ Metastatic Breast Cancer Treatment

Advancing Breast Cancer Care With Gammapod Radiation

Advancing Breast Cancer Care With Gammapod Radiation

Going the Distance With Metastatic Breast Cancer: 'Personal Best'

Going the Distance With Metastatic Breast Cancer: "Personal Best"

Endocrine Therapy Noninferior to Chemotherapy as First-Line Treatment for Patients with MBC

Endocrine Therapy Noninferior to Chemotherapy as First-Line Treatment for Patients with MBC

Neratinib and Capecitabine Improves PFS in HER2+ Metastatic Breast Cancer

Neratinib and Capecitabine Improves PFS in HER2+ Metastatic Breast Cancer

Durvalumab Provokes Robust Long-Term Outcomes in Patients with TNBC

Durvalumab Provokes Robust Long-Term Outcomes in Patients with TNBC

Dietary Supplement Use May Affect Recurrence, Mortality After Breast Cancer Treatment

Dietary Supplement Use May Affect Recurrence, Mortality After Breast Cancer Treatment

FDA Approves First Antibody-Drug Conjugate for TNBC

FDA Approves First Antibody-Drug Conjugate for TNBC

ASCO Guideline on Adjuvant Olaparib in Patients with HER2-negative Breast Cancer

ASCO Guideline on Adjuvant Olaparib in Patients with HER2-negative Breast Cancer

HER2CLIMB Study Shows Benefits of Triple Therapy for HER2+ Metastatic Breast Cancer with Brain Metastases

HER2CLIMB Study Shows Benefits of Triple Therapy for HER2+ Metastatic Breast Cancer with Brain Metastases

Impassion031 Outcomes Show Importance of Looking Beyond Initial Trial Data

Impassion031 Outcomes Show Importance of Looking Beyond Initial Trial Data

TNBC: Phase 3 ASCENT Study Halts Due to “Compelling Efficacy”

TNBC: Phase 3 ASCENT Study Halts Due to “Compelling Efficacy”

Helping Breast Cancer Oncologists Work ‘In the Trenches’

Helping Breast Cancer Oncologists Work ‘In the Trenches’

Adjuvant Olaparib Significantly Improves Invasive DFS in Patients with High-Risk EBC, BRCA Mutations

Adjuvant Olaparib Significantly Improves Invasive DFS in Patients with High-Risk EBC, BRCA Mutations

Large Epidemiology Study Updates Breast Cancer Risk for Women Lacking Family History

Large Epidemiology Study Updates Breast Cancer Risk for Women Lacking Family History

Preventing Breast Cancer in Women Carrying BRCA1 Gene

Preventing Breast Cancer in Women Carrying BRCA1 Gene

FDA Approves Sacituzumab Govitecan-hziy for Metastatic TNBC

FDA Approves Sacituzumab Govitecan-hziy for Metastatic TNBC

Combination Therapy Fails to Meet Primary Endpoints in HR+ HER2- Breast Cancer Treatment

Combination Therapy Fails to Meet Primary Endpoints in HR+ HER2- Breast Cancer Treatment

Chemotherapy Plus Treatment Combination for ERBB2-positive MBC Inferior in Clinical Practice

Chemotherapy Plus Treatment Combination for ERBB2-positive MBC Inferior in Clinical Practice

Immunotherapy/Chemo Combo Improves PFS in Metastatic Triple-Negative Breast Cancer

Immunotherapy/Chemo Combo Improves PFS in Metastatic Triple-Negative Breast Cancer

Metastatic Breast Cancer: 'The Journey Begins'

Metastatic Breast Cancer: "The Journey Begins"

Study Compares Digital Breast Tomosynthesis to Digital Mammography

Study Compares Digital Breast Tomosynthesis to Digital Mammography

Pembrolizumab Passes Two New Milestones for Triple-Negative Breast Cancer

Pembrolizumab Passes Two New Milestones for Triple-Negative Breast Cancer

Improving Outcomes for Early Onset Breast Cancer

Improving Outcomes for Early Onset Breast Cancer

FDA Approves Probe Cocktail Assay for HER2 Breast Cancer

FDA Approves Probe Cocktail Assay for HER2 Breast Cancer

Nobel Prize Winner Links Cancer Immunotherapy to Programmed Cell Death Gene

Nobel Prize Winner Links Cancer Immunotherapy to Programmed Cell Death Gene

FDA Approves New HER2+ Breast Cancer Therapy

FDA Approves New HER2+ Breast Cancer Therapy

Sacituzumab Govitecan Extends Survival in Metastatic Triple-Negative Breast Cancer

Sacituzumab Govitecan Extends Survival in Metastatic Triple-Negative Breast Cancer

New Uses for Existing Therapies in Breast Cancer Research

New Uses for Existing Therapies in Breast Cancer Research

Research Shows Benefits of Pembrolizumab as Single Agent TNBC Treatment

Research Shows Benefits of Pembrolizumab as Single Agent TNBC Treatment

Combining Eribulin and Pembrolizumab in Metastatic Triple-Negative Breast Cancer

Combining Eribulin and Pembrolizumab in Metastatic Triple-Negative Breast Cancer

Understanding Recent Breast Cancer Vaccine Breakthroughs

Understanding Recent Breast Cancer Vaccine Breakthroughs

European Regulators Validate TNBC Biologic Treatment Application

European Regulators Validate TNBC Biologic Treatment Application

European Breast Cancer Guidelines Highlight Difficulties in Minimizing Risk

European Breast Cancer Guidelines Highlight Difficulties in Minimizing Risk

New Study Questions Need for Immediate Treatment for All Breast Cancer

New Study Questions Need for Immediate Treatment for All Breast Cancer

Genetic Testing May Influence Breast Cancer Treatment that Goes Against Practice Guidelines

Genetic Testing May Influence Breast Cancer Treatment that Goes Against Practice Guidelines

Study Shows Tolerable Safety of Abemaciclib Plus Pembrolizumab in HER2-, Metastatic Breast Cancer

Study Shows Tolerable Safety of Abemaciclib Plus Pembrolizumab in HER2-, Metastatic Breast Cancer

FDA Rejects Breast Cancer Therapy Due to Safety Concerns

FDA Rejects Breast Cancer Therapy Due to Safety Concerns

FDA Approves New Treatment for HER2-Positive Breast Cancer

FDA Approves New Treatment for HER2-Positive Breast Cancer

Oncologist Explains How Gammapod Works for Breast Cancer

Oncologist Explains How Gammapod Works for Breast Cancer

Abemaciclib Represents ‘New Standard of Care’ for Patients With High-Risk Early Breast Cancer

Abemaciclib Represents ‘New Standard of Care’ for Patients With High-Risk Early Breast Cancer

Pembrolizumab + Chemotherapy Beneficial in Triple-Negative Breast Cancer

Pembrolizumab + Chemotherapy Beneficial in Triple-Negative Breast Cancer

1:25 MD /Alert Exclusive

FDA Clears First Clinical Trial for Breast Cancer Vaccine

Why Dual Light Therapy Hits Triple Negative Breast Cancer Harder

Why Dual Light Therapy Hits Triple Negative Breast Cancer Harder

Biosimilar Trastuzumab-dttb Launched for Treatment of HER2+ Breast Cancer

Biosimilar Trastuzumab-dttb Launched for Treatment of HER2+ Breast Cancer

Neratinib + Capecitabine Improves QoL for HER2+ Metastatic Breast Cancer

Neratinib + Capecitabine Improves QoL for HER2+ Metastatic Breast Cancer

MINDACT Study Shows Continued Success in Determining Chemotherapy Usage

MINDACT Study Shows Continued Success in Determining Chemotherapy Usage

Study of Immunotherapy Combinations for Patients with Metastatic Breast Cancer

Study of Immunotherapy Combinations for Patients with Metastatic Breast Cancer

Genomic Profiling Improves Metastatic Breast Cancer Research

Genomic Profiling Improves Metastatic Breast Cancer Research

Breaking Study Finds Optimal Screening Interval for Breast Cancer

Breaking Study Finds Optimal Screening Interval for Breast Cancer

Time to Treatment Completion Associated with Poor Breast Cancer Survival

Time to Treatment Completion Associated with Poor Breast Cancer Survival

Studies Emphasizes Need for Universal Testing in Breast Cancer Treatment

Studies Emphasizes Need for Universal Testing in Breast Cancer Treatment

MD /Alert Exclusives

Celecoxib Shows No Benefit for Patients with Early Breast Cancer

Celecoxib Shows No Benefit for Patients with Early Breast Cancer

Research Shows Benefits of Pembrolizumab as Single Agent TNBC Treatment

Research Shows Benefits of Pembrolizumab as Single Agent TNBC Treatment

Chemotherapy Plus Treatment Combination for ERBB2-positive MBC Inferior in Clinical Practice

Chemotherapy Plus Treatment Combination for ERBB2-positive MBC Inferior in Clinical Practice

ASCO Guideline on Adjuvant Olaparib in Patients with HER2-negative Breast Cancer

ASCO Guideline on Adjuvant Olaparib in Patients with HER2-negative Breast Cancer

Durvalumab Provokes Robust Long-Term Outcomes in Patients with TNBC

Durvalumab Provokes Robust Long-Term Outcomes in Patients with TNBC

Endocrine Therapy Noninferior to Chemotherapy as First-Line Treatment for Patients with MBC

Endocrine Therapy Noninferior to Chemotherapy as First-Line Treatment for Patients with MBC

Adjuvant Olaparib Significantly Improves Invasive DFS in Patients with High-Risk EBC, BRCA Mutations

Adjuvant Olaparib Significantly Improves Invasive DFS in Patients with High-Risk EBC, BRCA Mutations

FDA Approves Sacituzumab Govitecan-hziy for Metastatic TNBC

FDA Approves Sacituzumab Govitecan-hziy for Metastatic TNBC

European Regulators Validate TNBC Biologic Treatment Application

European Regulators Validate TNBC Biologic Treatment Application

FDA Rejects Breast Cancer Therapy Due to Safety Concerns

FDA Rejects Breast Cancer Therapy Due to Safety Concerns

Large Epidemiology Study Updates Breast Cancer Risk for Women Lacking Family History

Large Epidemiology Study Updates Breast Cancer Risk for Women Lacking Family History

FDA Committee Delays Approval of Pembrolizumab for Early TNBC

FDA Committee Delays Approval of Pembrolizumab for Early TNBC

1:25 MD /Alert Exclusive

FDA Clears First Clinical Trial for Breast Cancer Vaccine

Helping Breast Cancer Oncologists Work ‘In the Trenches’

Helping Breast Cancer Oncologists Work ‘In the Trenches’

New ASCO, ASTRO, SSO Joint Clinical Guidelines for Hereditary Breast Cancer

New ASCO, ASTRO, SSO Joint Clinical Guidelines for Hereditary Breast Cancer

EU approves HER2+ Metastatic Breast Cancer Treatment

EU approves HER2+ Metastatic Breast Cancer Treatment

Studies Emphasizes Need for Universal Testing in Breast Cancer Treatment

Studies Emphasizes Need for Universal Testing in Breast Cancer Treatment

Impassion031 Outcomes Show Importance of Looking Beyond Initial Trial Data

Impassion031 Outcomes Show Importance of Looking Beyond Initial Trial Data

Combination Therapy Fails to Meet Primary Endpoints in HR+ HER2- Breast Cancer Treatment

Combination Therapy Fails to Meet Primary Endpoints in HR+ HER2- Breast Cancer Treatment

Mindfulness Shows Benefits for Young Breast Cancer

Mindfulness Shows Benefits for Young Breast Cancer

Time to Treatment Completion Associated with Poor Breast Cancer Survival

Time to Treatment Completion Associated with Poor Breast Cancer Survival

Neratinib + Capecitabine Improves QoL for HER2+ Metastatic Breast Cancer

Neratinib + Capecitabine Improves QoL for HER2+ Metastatic Breast Cancer

Study Shows Breastfeeding Can be Safe for Breast Cancer Survivors

Study Shows Breastfeeding Can be Safe for Breast Cancer Survivors

Abemaciclib Represents ‘New Standard of Care’ for Patients With High-Risk Early Breast Cancer

Abemaciclib Represents ‘New Standard of Care’ for Patients With High-Risk Early Breast Cancer

Sacituzumab Govitecan Extends Survival in Metastatic Triple-Negative Breast Cancer

Sacituzumab Govitecan Extends Survival in Metastatic Triple-Negative Breast Cancer

FDA Issues Warning Alert for Atezolizumab/Paclitaxel Combo in TNBC

FDA Issues Warning Alert for Atezolizumab/Paclitaxel Combo in TNBC

Nobel Prize Winner Links Cancer Immunotherapy to Programmed Cell Death Gene

Nobel Prize Winner Links Cancer Immunotherapy to Programmed Cell Death Gene

Neratinib and Capecitabine Improves PFS in HER2+ Metastatic Breast Cancer

Neratinib and Capecitabine Improves PFS in HER2+ Metastatic Breast Cancer

Pembrolizumab Passes Two New Milestones for Triple-Negative Breast Cancer

Pembrolizumab Passes Two New Milestones for Triple-Negative Breast Cancer

FDA Approves Probe Cocktail Assay for HER2 Breast Cancer

FDA Approves Probe Cocktail Assay for HER2 Breast Cancer

Study Compares Digital Breast Tomosynthesis to Digital Mammography

Study Compares Digital Breast Tomosynthesis to Digital Mammography

1:52 MD /Alert Exclusive

FDA Approves Mammography Screening Artificial Intelligence Tool

Adding Capecitabine to TDM-1 Demonstrates No Benefit in Breast Cancer Patients

Adding Capecitabine to TDM-1 Demonstrates No Benefit in Breast Cancer Patients

Early Study Results show Abemaciclib Reduces Risk of Recurrence in HR+ HER2- Breast Cancer

Early Study Results show Abemaciclib Reduces Risk of Recurrence in HR+ HER2- Breast Cancer

MINDACT Study Shows Continued Success in Determining Chemotherapy Usage

MINDACT Study Shows Continued Success in Determining Chemotherapy Usage

Pembrolizumab + Chemotherapy Beneficial in Triple-Negative Breast Cancer

Pembrolizumab + Chemotherapy Beneficial in Triple-Negative Breast Cancer

Advanced ER+ HER2+ Breast Cancer Combo Therapy Fails to Improve Outcomes

Advanced ER+ HER2+ Breast Cancer Combo Therapy Fails to Improve Outcomes

HER2CLIMB Study Shows Benefits of Triple Therapy for HER2+ Metastatic Breast Cancer with Brain Metastases

HER2CLIMB Study Shows Benefits of Triple Therapy for HER2+ Metastatic Breast Cancer with Brain Metastases

Breast Cancer Survivors Report Cognitive Impairment After PPI Use

Breast Cancer Survivors Report Cognitive Impairment After PPI Use

Biosimilar Trastuzumab-dttb Launched for Treatment of HER2+ Breast Cancer

Biosimilar Trastuzumab-dttb Launched for Treatment of HER2+ Breast Cancer

FDA Approves First Antibody-Drug Conjugate for TNBC

FDA Approves First Antibody-Drug Conjugate for TNBC

TNBC: Phase 3 ASCENT Study Halts Due to “Compelling Efficacy”

TNBC: Phase 3 ASCENT Study Halts Due to “Compelling Efficacy”

Genetic Testing May Influence Breast Cancer Treatment that Goes Against Practice Guidelines

Genetic Testing May Influence Breast Cancer Treatment that Goes Against Practice Guidelines

New Study Questions Need for Immediate Treatment for All Breast Cancer

New Study Questions Need for Immediate Treatment for All Breast Cancer

FDA Approves New HER2+ Breast Cancer Therapy

FDA Approves New HER2+ Breast Cancer Therapy

Immunotherapy/Chemo Combo Improves PFS in Metastatic Triple-Negative Breast Cancer

Immunotherapy/Chemo Combo Improves PFS in Metastatic Triple-Negative Breast Cancer

Dietary Supplement Use May Affect Recurrence, Mortality After Breast Cancer Treatment

Dietary Supplement Use May Affect Recurrence, Mortality After Breast Cancer Treatment

Adding Tucatinib to Trastuzumab and Capecitabine Improves HER2-positive Breast Cancer Survival

Adding Tucatinib to Trastuzumab and Capecitabine Improves HER2-positive Breast Cancer Survival

European Breast Cancer Guidelines Highlight Difficulties in Minimizing Risk

European Breast Cancer Guidelines Highlight Difficulties in Minimizing Risk

FDA Approves New Treatment for HER2-Positive Breast Cancer

FDA Approves New Treatment for HER2-Positive Breast Cancer

Breaking Study Finds Optimal Screening Interval for Breast Cancer

Breaking Study Finds Optimal Screening Interval for Breast Cancer

FDA Warns of Cancer Risk After Mastectomy, Reconstruction

FDA Warns of Cancer Risk After Mastectomy, Reconstruction

New Breast Cancer Therapy Shows Significant Response

New Breast Cancer Therapy Shows Significant Response

SABCS 2020 Annual Meeting

FDA Committee Delays Approval of Pembrolizumab for Early TNBC

FDA Committee Delays Approval of Pembrolizumab for Early TNBC

1:25 MD /Alert Exclusive

FDA Clears First Clinical Trial for Breast Cancer Vaccine

Helping Breast Cancer Oncologists Work ‘In the Trenches’

Helping Breast Cancer Oncologists Work ‘In the Trenches’

EU approves HER2+ Metastatic Breast Cancer Treatment

EU approves HER2+ Metastatic Breast Cancer Treatment

Studies Emphasizes Need for Universal Testing in Breast Cancer Treatment

Studies Emphasizes Need for Universal Testing in Breast Cancer Treatment

Impassion031 Outcomes Show Importance of Looking Beyond Initial Trial Data

Impassion031 Outcomes Show Importance of Looking Beyond Initial Trial Data

Combination Therapy Fails to Meet Primary Endpoints in HR+ HER2- Breast Cancer Treatment

Combination Therapy Fails to Meet Primary Endpoints in HR+ HER2- Breast Cancer Treatment

Mindfulness Shows Benefits for Young Breast Cancer

Mindfulness Shows Benefits for Young Breast Cancer

Time to Treatment Completion Associated with Poor Breast Cancer Survival

Time to Treatment Completion Associated with Poor Breast Cancer Survival

Neratinib + Capecitabine Improves QoL for HER2+ Metastatic Breast Cancer

Neratinib + Capecitabine Improves QoL for HER2+ Metastatic Breast Cancer

ASCO 2020 Annual Meeting

MINDACT Study Shows Continued Success in Determining Chemotherapy Usage

MINDACT Study Shows Continued Success in Determining Chemotherapy Usage

Pembrolizumab + Chemotherapy Beneficial in Triple-Negative Breast Cancer

Pembrolizumab + Chemotherapy Beneficial in Triple-Negative Breast Cancer

Advanced ER+ HER2+ Breast Cancer Combo Therapy Fails to Improve Outcomes

Advanced ER+ HER2+ Breast Cancer Combo Therapy Fails to Improve Outcomes

HER2CLIMB Study Shows Benefits of Triple Therapy for HER2+ Metastatic Breast Cancer with Brain Metastases

HER2CLIMB Study Shows Benefits of Triple Therapy for HER2+ Metastatic Breast Cancer with Brain Metastases

Study Shows Tolerable Safety of Abemaciclib Plus Pembrolizumab in HER2-, Metastatic Breast Cancer

Study Shows Tolerable Safety of Abemaciclib Plus Pembrolizumab in HER2-, Metastatic Breast Cancer

Combining Eribulin and Pembrolizumab in Metastatic Triple-Negative Breast Cancer

Combining Eribulin and Pembrolizumab in Metastatic Triple-Negative Breast Cancer

Featured Breast Cancer Videos

Going the Distance With Metastatic Breast Cancer: 'Personal Best'

Going the Distance With Metastatic Breast Cancer: "Personal Best"

Metastatic Breast Cancer: 'The Journey Begins'

Metastatic Breast Cancer: "The Journey Begins"

Breaking Research

Personalized Assay Surpasses Limits for Detecting Tumor DNA in Breast Cancer Patients

Personalized Assay Surpasses Limits for Detecting Tumor DNA in Breast Cancer Patients

Overcoming Treatment Resistance in Breast Cancer

Overcoming Treatment Resistance in Breast Cancer

Oncologist Explains How Gammapod Works for Breast Cancer

Oncologist Explains How Gammapod Works for Breast Cancer

Advancing Breast Cancer Care With Gammapod Radiation

Advancing Breast Cancer Care With Gammapod Radiation

RNA TROJAN Promotes Triple-Negative Breast Cancer Progression

RNA TROJAN Promotes Triple-Negative Breast Cancer Progression

Preventing Breast Cancer in Women Carrying BRCA1 Gene

Preventing Breast Cancer in Women Carrying BRCA1 Gene

Curated For You

Genomic Profiling Improves Metastatic Breast Cancer Research

Genomic Profiling Improves Metastatic Breast Cancer Research

New Uses for Existing Therapies in Breast Cancer Research

New Uses for Existing Therapies in Breast Cancer Research

Various Breast Cancer Research Challenges in Recurrence, Triple Negative BC

Various Breast Cancer Research Challenges in Recurrence, Triple Negative BC

Understanding Recent Breast Cancer Vaccine Breakthroughs

Understanding Recent Breast Cancer Vaccine Breakthroughs

Study of Immunotherapy Combinations for Patients with Metastatic Breast Cancer

Study of Immunotherapy Combinations for Patients with Metastatic Breast Cancer

Why Dual Light Therapy Hits Triple Negative Breast Cancer Harder

Why Dual Light Therapy Hits Triple Negative Breast Cancer Harder

Improving Outcomes for Early Onset Breast Cancer

Improving Outcomes for Early Onset Breast Cancer